東華大學圖書館 |

Language: English

Help

回圖書館首頁

手機版館藏查詢

Back

Switch To: Labeled | MARC Mode | ISBD

Hepatitis virus reactivation in canc...

Yeo, Winnie.

Linked to FindBook

Google Book

Amazon

博客來

Hepatitis virus reactivation in cancer patients undergoing cytotoxic chemotherapy: Incidences, associated factors and management.

Record Type:	Language materials, printed : Monograph/item
Title/Author:	Hepatitis virus reactivation in cancer patients undergoing cytotoxic chemotherapy: Incidences, associated factors and management./
Author:	Yeo, Winnie.
Description:	256 p.
Notes:	Adviser: P. J. Johnson.
Contained By:	Dissertation Abstracts International63-05B.
Subject:	Health Sciences, Medicine and Surgery. -
Online resource:	http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=3052092
ISBN:	0493675590

Hepatitis virus reactivation in cancer patients undergoing cytotoxic chemotherapy: Incidences, associated factors and management.
Yeo, Winnie.

Hepatitis virus reactivation in cancer patients undergoing cytotoxic chemotherapy: Incidences, associated factors and management. - 256 p.

Adviser: P. J. Johnson.

Thesis (M.D.)--Chinese University of Hong Kong (People's Republic of China), 2001.

Chronic hepatitis B virus (HBV) infection is endemic in many parts of the world including Hong Kong. HBV reactivation is a well-described and potentially fatal complication in cancer patients who receive cytotoxic chemotherapy. The reactivation is characterized by raised levels of serum HBV DNA, abnormal liver function tests and clinical hepatitis of varying severity. The aims of this thesis were firstly to determine the frequency of HBV reactivation in cancer patients undergoing cytotoxic chemotherapy and to identify the associated risk factors, and secondly to address treatment strategies that can be administered to patients in preventing and controlling the severity of this condition. The following studies have been conducted for these objectives. In a prospective study, patients who were HBsAg positive were followed up during their course of chemotherapy. HBV reactivation was found to occur in nearly 20% of them and accounts for 44% of hepatitis cases. Factors associated with the development of HBV reactivation included male gender, young age, HBeAg positivity and a diagnosis of lymphoma. In two separate studies, the role of HBV mutants in HBeAg-negative HBV reactivation were assessed. Chronic HBV carriers who were HBeAg negative/anti-HBe positive with nt 1896 mutation (G to A) appeared to be more likely to develop HBV reactivation during cytotoxic chemotherapy, and the latter did not appear to associate with the emergence of mutant HBV. With respect to the treatment of HBV reactivation, the use of anti-viral agent, lamivudine, was found to associate with HBV DNA suppression, although the delay in the administration of the anti-viral could still be associated with poor outcome. When lamivudine was administered prior to the commencement of chemotherapy, the incidence and the severity of HBV reactivation in cancer patients undergoing chemotherapy appeared to be reduced. It was concluded that for 20% of HBV carriers developed HBV reactivation during cytotoxic chemotherapy, and the associated risk factors included male gender, young age, HBeAg seropositivity, mutant HBV and a diagnosis of lymphoma. Use of lamivudine appeared to be effective in controlling the condition.

ISBN: 0493675590Subjects--Topical Terms:

1017756
Health Sciences, Medicine and Surgery.

Hepatitis virus reactivation in cancer patients undergoing cytotoxic chemotherapy: Incidences, associated factors and management.
LDR:03172nam 2200277 a 45 001 934094
005 20110509
008 110509s2001 eng d
020 $a 0493675590
035 $a (UnM)AAI3052092
035 $a AAI3052092
040 $a UnM $c UnM
100 1 $a Yeo, Winnie. $3 1257818
245 1 0 $a Hepatitis virus reactivation in cancer patients undergoing cytotoxic chemotherapy: Incidences, associated factors and management.
300 $a 256 p.
500 $a Adviser: P. J. Johnson.
500 $a Source: Dissertation Abstracts International, Volume: 63-05, Section: B, page: 2297.
502 $a Thesis (M.D.)--Chinese University of Hong Kong (People's Republic of China), 2001.
520 $a Chronic hepatitis B virus (HBV) infection is endemic in many parts of the world including Hong Kong. HBV reactivation is a well-described and potentially fatal complication in cancer patients who receive cytotoxic chemotherapy. The reactivation is characterized by raised levels of serum HBV DNA, abnormal liver function tests and clinical hepatitis of varying severity. The aims of this thesis were firstly to determine the frequency of HBV reactivation in cancer patients undergoing cytotoxic chemotherapy and to identify the associated risk factors, and secondly to address treatment strategies that can be administered to patients in preventing and controlling the severity of this condition. The following studies have been conducted for these objectives. In a prospective study, patients who were HBsAg positive were followed up during their course of chemotherapy. HBV reactivation was found to occur in nearly 20% of them and accounts for 44% of hepatitis cases. Factors associated with the development of HBV reactivation included male gender, young age, HBeAg positivity and a diagnosis of lymphoma. In two separate studies, the role of HBV mutants in HBeAg-negative HBV reactivation were assessed. Chronic HBV carriers who were HBeAg negative/anti-HBe positive with nt 1896 mutation (G to A) appeared to be more likely to develop HBV reactivation during cytotoxic chemotherapy, and the latter did not appear to associate with the emergence of mutant HBV. With respect to the treatment of HBV reactivation, the use of anti-viral agent, lamivudine, was found to associate with HBV DNA suppression, although the delay in the administration of the anti-viral could still be associated with poor outcome. When lamivudine was administered prior to the commencement of chemotherapy, the incidence and the severity of HBV reactivation in cancer patients undergoing chemotherapy appeared to be reduced. It was concluded that for 20% of HBV carriers developed HBV reactivation during cytotoxic chemotherapy, and the associated risk factors included male gender, young age, HBeAg seropositivity, mutant HBV and a diagnosis of lymphoma. Use of lamivudine appeared to be effective in controlling the condition.
590 $a School code: 1307.
650 4 $a Health Sciences, Medicine and Surgery. $3 1017756
650 4 $a Health Sciences, Oncology. $3 1018566
690 $a 0564
690 $a 0992
710 2 0 $a Chinese University of Hong Kong (People's Republic of China). $3 1249360
773 0 $t Dissertation Abstracts International $g 63-05B.
790 $a 1307
790 1 0 $a Johnson, P. J., $e advisor
791 $a M.D.
792 $a 2001
856 4 0 $u http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=3052092